Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/20/2005US6977294 Process for isolation of eupalitin from Boerhavia diffusa
12/20/2005US6977272 Prophylaxis or prevention of neurotoxic effects of alcoholic beverages by contacting immunoglobulins with 3-pentanol, 2-pentanol, cyclopentanol, 4-methyl-1-pentanol, decanol, 2-methyl-2-pentanol or 2,6- diisopropylphenol
12/20/2005US6977271 Treat solid tumors with Conjugated Linoleic Acid isomers administered orally
12/20/2005US6977270 Tocotrienolquinone cyclization product with an anti-hypercholesterol effect
12/20/2005US6977269 Method of improving animal tissue quality
12/20/2005US6977268 Diacid isoindoleine amide derivative
12/20/2005US6977267 Spiro-hydantoin compounds useful as anti-inflammatory agents
12/20/2005US6977264 For therapy and prophylaxis of obesity, diabetes
12/20/2005US6977263 Chemical compounds
12/20/2005US6977260 Piperidinyl prostaglandin E analogs
12/20/2005US6977259 Quinoline derivatives and their use as aurora 2 kinase inhibitors
12/20/2005US6977258 Antiinflammatory agents; cardiotonic agents; rheumatic diseases
12/20/2005US6977257 Aripiprazole oral solution
12/20/2005US6977255 8-Substituted 2-morpholinyl-4H-pyrido(1,2-a)pyrimidin-4-ones inhibitor of phosphoinositide (PI) 3- kinase, an enzyme that regulates platelet-adhesion (antithrombotic agent)
12/20/2005US6977254 For prevention and/or suppression of preterm labor, suppression labor at term prior to caesarean deliver, and for the treatment of dysmenorrhea, useful in enhancing fertility rates
12/20/2005US6977253 Methods for the treatment of bipolar disorder using carbamazepine
12/20/2005US6977252 Use of 1,4-benzothiazepine derivatives as drugs for overcoming resistance to anticancer drugs
12/20/2005US6977251 5-androstene-3β, 17α diol as an inhibitor of tumor growth
12/20/2005US6977250 Prevention of ovarian cancer by administration of progestin products
12/20/2005US6977249 molecular weight reduction of dextran by hydrolysis, hydrogenation, and oxidation; complexing with ferric oxy-hydroxide; narrow molecular weight distribution controlled by the ratio of hydrogenated/oxygenated groups; improved stability; anemia
12/20/2005US6977248 Heparan sulfate polysaccharide enriched 5%-7% for 3-o-sulfated glucosamine residues by (3'-phosphoadenosine 5'-phosphosulfate) a sulfur donor, and a sulfotransferase; specific saccahride sequences are binding receptors for viral envelope protein gD
12/20/2005US6977247 Administering to a cancer patient a 20(S)- camptothecin for a period of time during which a pyrimidine base analog such as 5-fluorouracil or 5-fluorocysteine in not being administered and administering the pyrimidine base to the cancer patient
12/20/2005US6977246 Certain dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
12/20/2005US6977245 Oligodeoxynucleotide and its use to induce an immune response
12/20/2005US6977244 Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
12/20/2005US6977243 Crystal forms of azithromycin
12/20/2005US6977167 Mixtures of omega-3 and omega-6 highly unsaturated fatty acids from euryhaline microorganisms
12/20/2005US6977158 Mammalian IAP gene family, primers, probes, and detection methods
12/20/2005US6977087 Administering to the respiratory system of a patient or animal hormone aerodynamically light particles, wherein particles are delivered and deposited to patient's or animal's lungs and hormone is released in patient's or animal's blood stream
12/20/2005US6977086 with improved strawberry and creamy flavoring; dry powder form; organoleptics; increased shelf life; pediatrics
12/20/2005US6977085 Dissolving first quantity of pharmaceutically-active compound in water-miscible first organic solvent to form a first solution; mixing first solution with second solvent to precipitate pharmaceutically-active compound; seeding
12/20/2005US6977081 an emollient cream of sulfur, sodium sulfacetimide, allantoin, water, sodium thiosulfate, methyl paraben, propylene glycol, stearic acid, PEG-8 stearate, emulsifying wax, isopropyl myristate, propylene glycol stearate, propyl paraben; pH of 7
12/20/2005US6977076 Immunomoderators; high molecular weight polysaccharides
12/20/2005US6977072 Unblocking immunization at a regional lymph node by: promoting differentiation and maturation of immature dendritic cells in a regional lymph node and; allowing presentation by resulting mature dendritic cells of antigen to T-cells
12/20/2005US6977070 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
12/20/2005CA2338206C High affinity ligands for nociceptin receptor orl-1
12/20/2005CA2329703C Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
12/20/2005CA2328903C Compounds capable of cleaving double-stranded dna and method of utilization of the same
12/20/2005CA2324324C Treatment of pulmonary hypertension
12/20/2005CA2322432C Pharmaceutical composition containing cefuroxime axetil stable for moisture absorption
12/20/2005CA2302412C Aminoalkylphenol derivatives and related compounds
12/20/2005CA2290966C Sertraline salts and sustained-release dosage forms of sertraline
12/20/2005CA2275593C Micro-particulate form of a tetrahydropyridin derivative
12/20/2005CA2266319C Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
12/20/2005CA2238516C Acyclic nucleoside derivatives
12/20/2005CA2233560C Sulfonamide inhibitors of matrix metalloproteinases
12/20/2005CA2199778C Extended release formulation of venlafaxine
12/20/2005CA2181569C Ep2-receptor agonists as agents for lowering intraocular pressure
12/20/2005CA2176962C N-substituted azabicycloheptane derivatives, their preparation and use
12/20/2005CA2159481C Tetracyclic compounds as dopamine agonists
12/20/2005CA2135251C Crystal modification of (4-cyclopropyl-6-methyl-pyrimidin-2-yl)-phenyl-amine
12/20/2005CA2114007C Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
12/20/2005CA2092896C Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
12/20/2005CA2038025C Optically active alkylenedioxybenzene derivatives and their use in therapy
12/18/2005WO2007049098A2 Therapeutic formulations for the treatment of beta-amyloid related diseases
12/18/2005CA2582385A1 Therapeutic formulations for the treatment of beta-amyloid related diseases
12/18/2005CA2504471A1 Pharmaceutical formulations of amyloid inhibiting compounds
12/18/2005CA2472695A1 Production of mutant strain of aspergillus fumigatus and method and assay for inhibiting siderophore biosynthesis
12/16/2005CA2505103A1 Nutritional supplement for adults
12/16/2005CA2505043A1 Nutritional supplement for infants
12/15/2005WO2005119252A2 Modulators of gpr35 for the treatment of metabolic-related disorders
12/15/2005WO2005118876A2 Egfr mutations
12/15/2005WO2005118811A1 Novel polypeptide useful for diagnosis and treatment of cancer
12/15/2005WO2005118777A2 Novel saccharothrix strain and antibiotics derived therefrom, i.e. mutactimycins and aldgamycins
12/15/2005WO2005118776A1 Selenium-enriched biomass, method for preparing thereof and probiotic and nutraceutical products including said biomass
12/15/2005WO2005118618A1 Substituted propane phosphinic acid derivatives
12/15/2005WO2005118612A1 Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs
12/15/2005WO2005118607A1 Production of hyaluronates
12/15/2005WO2005118601A2 Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
12/15/2005WO2005118594A1 Muscarinic acetylcholine receptor antagonists
12/15/2005WO2005118593A1 Bicyclic heterocycles as hiv integrase inhibitors
12/15/2005WO2005118591A1 Condensed piperidine compounds acting as adrenergic receptor antagonists useful in the treatment of prostatic hyperplasia and lower urinary symptoms
12/15/2005WO2005118590A1 Bicyclic heterocycles as hiv integrase inhibitors
12/15/2005WO2005118589A1 Bicyclic heterocycles as hiv integrase inhibitors
12/15/2005WO2005118588A1 Fused heterocyclic compound
12/15/2005WO2005118584A2 Saframycin analogs as therapeutic agents in the treatment of cancer
12/15/2005WO2005118583A1 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors
12/15/2005WO2005118582A1 Corneal perception recovery drug containing amide compound
12/15/2005WO2005118580A2 Tricyclic compounds as inhibitors of the hypoxic signaling pathway
12/15/2005WO2005118579A2 Thiazole derivatives as chemokine receptor antagonists
12/15/2005WO2005118578A1 Mercaptoimidazoles as ccr2 receptor antagonists
12/15/2005WO2005118577A1 Novel saperconazole crystalline forms and related processes, pharmaceutical compositions and methods
12/15/2005WO2005118576A1 Constrained himbacine analogs as thrombin receptor antagonists
12/15/2005WO2005118575A1 Non nucleoside reverse transcriptase inhibitors
12/15/2005WO2005118572A1 Quinazoline derivatives as erbb receptor tyrosine kinases
12/15/2005WO2005118571A1 Pyridin-2-one compounds and their use as modulators of the dopamine d3 receptor
12/15/2005WO2005118567A2 Magnesium complexes of s-omeprazole
12/15/2005WO2005118564A2 Methods for the synthesis of milnacipran and congeners thereof
12/15/2005WO2005118559A1 A type of formyl peptide receptor-like 1 regulator, preparation method and use thereof
12/15/2005WO2005118558A2 Pyrimidine compounds and use thereof
12/15/2005WO2005118556A1 Propane-1,3-dione derivative or its salt
12/15/2005WO2005118555A1 Dipeptidyl peptidase inhibitors
12/15/2005WO2005118547A1 Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics
12/15/2005WO2005118543A1 Kinase inhibitor and use thereof
12/15/2005WO2005118539A1 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor
12/15/2005WO2005118538A2 Arylsulfonamides and uses as hydroxysteroid dehydrogenase
12/15/2005WO2005118535A1 Substituted pyrrolidine-2-ones
12/15/2005WO2005118511A2 Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
12/15/2005WO2005118166A2 Pharmaceutical composition containing irbesartan
12/15/2005WO2005118071A2 Tetrahydropyridothiophenes
1 ... 4430 4431 4432 4433 4434 4435 4436 4437 4438 4439 4440 4441 4442 4443 4444 4445 4446 4447 4448 4449 4450 ... 7860